National survey of extended-interval aminoglycoside dosing

被引:69
|
作者
Chuck, SK
Raber, SR
Rodvold, KA
Areff, D
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA
[2] Univ Illinois, Coll Med, Infect Dis Sect, Chicago, IL 60612 USA
[3] Oregon State Univ, Coll Pharm, Portland, OR USA
[4] Providence Med Ctr, Dept Pharm, Portland, OR USA
[5] Providence Med Ctr, Dept Med Educ, Portland, OR USA
关键词
D O I
10.1086/313692
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A random sample survey of 500 acute care hospitals in the United States was conducted to evaluate the adoption of extended-interval aminoglycoside dosing (EIAD). The survey revealed that EIAD has been adopted in 3 of every 4 acute care hospitals, a 4-fold increase since 1993. Of the 74.7% of hospitals reporting EIAD, 64% had written guidelines. Equal or less toxicity (87.1%), equal efficacy (76.9%), and cost-savings (65.6%) were common rationales. There has been a trend toward higher adult dosages of gentamicin (e.g., >5 mg/kg/dose) and an increase in the adoption of EIAD across all age groups (neonatal, 11%, and pediatric, 23%). Monitoring of aminoglycoside concentrations has shifted to a single determination of concentration, at 6-18 h after drug administration. The most common methods of dosage adjustment for declining renal function were an interval extension with the same dose (47%) or use of the Hartford nomogram (32%).
引用
收藏
页码:433 / 439
页数:7
相关论文
共 50 条
  • [21] COMPLIANCE EVALUATION OF HIGH-DOSE EXTENDED-INTERVAL AMINOGLYCOSIDE PHARMACY PROTOCOL
    Peton, A.
    Herrmann, D. M.
    Lopez, W.
    [J]. PEDIATRIC PULMONOLOGY, 2020, 55 : S252 - S253
  • [22] Extended-interval dosing of tobramycin in neonates: Implications for therapeutic drug monitoring
    de Hoog, M
    Mouton, JW
    Schoemaker, RC
    Verduin, CM
    van den Anker, JN
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (05) : 349 - 358
  • [23] The Use of Extended-Interval Aminoglycoside Dosing Strategies for the Treatment of Moderate-to-Severe Infections Encountered in Critically III Surgical Patients
    Mueller, Eric W.
    Boucher, Bradley A.
    [J]. SURGICAL INFECTIONS, 2009, 10 (06) : 563 - 570
  • [24] DETERMINATION OF INDICATION-BASED, EXTENDED-INTERVAL GENTAMICIN DOSING REGIMENS FOR NEONATES
    Rychalsky, Michelle
    Rowcliffe, Meghan
    vital-Carona, Jessica
    Broome, Laura
    Kelly, Sarah
    Bizzarro, Matthew
    [J]. CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [25] Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
    Wiederhold, Nathan P.
    Najvar, Laura K.
    Jaramillo, Rosie
    Olivo, Marcos
    Wickes, Brian L.
    Catano, Gabriel
    Patterson, Thomas F.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (10)
  • [26] Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries
    Darmstadt, Gary L.
    Miller-Bell, Mary
    Batra, Maneesh
    Law, Paul
    Law, Kiely
    [J]. JOURNAL OF HEALTH POPULATION AND NUTRITION, 2008, 26 (02) : 163 - 182
  • [27] Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC
    Pierre, Clemence
    Goter, Thomas
    Lena, Herve
    Le Guen, Yannick
    Ricordel, Charles
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : E14 - E16
  • [28] Natalizumab extended-interval dosing in a real-life context: efficacy study
    Jeantin, L.
    De la Motte, M. Boudot
    Chauvin, M.
    Dade, M.
    Deschamps, R.
    Gueguen, A.
    Mossad, M.
    Diallo, S. S.
    Gout, O.
    Bensa, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 852 - 853
  • [29] Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system
    Bryant, Alex K.
    Lewy, Jacqueline R.
    Bressler, R. Daniel
    Chopra, Zoey
    Gyori, Derek J.
    Bazzell, Brian G.
    Moeller, Julie A.
    Jacobson, Sofia, I
    Fendrick, A. Mark
    Kerr, Eve A.
    Ramnath, Nithya
    Green, Michael D.
    Hofer, Timothy P.
    Vaishnav, Parth
    Strohbehn, Garth W.
    [J]. LANCET ONCOLOGY, 2024, 25 (06): : 802 - 810
  • [30] Some international approaches to aminoglycoside monitoring in the extended dosing interval era
    Morris, RG
    Sallustio, BC
    Vinks, TATMM
    LeGatt, DF
    Verjee, ZH
    El Desoky, E
    [J]. THERAPEUTIC DRUG MONITORING, 1999, 21 (04) : 379 - 388